Checkpoint blockade in combination with cancer vaccines

Related Experiment Video

Updated: Mar 31, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

Michael A Morse1, H Kim Lyerly2

  • 1Department of Medicine, Duke University Medical Center, Durham, NC, United States.

Vaccine
|October 21, 2015
PubMed

Insights

Checkpoint blockade immunotherapy, using antibodies against CTLA-4 and PD-1, shows promise for cancer treatment. Combining these therapies with cancer vaccines may enhance anti-tumor activity, though clinical results require further investigation.

Area of Science:

  • Immunology
  • Oncology
  • Cancer Therapy

Background:

  • Checkpoint blockade immunotherapy, targeting CTLA-4 and PD-1, is transforming cancer treatment for advanced malignancies.
  • Many tumors exhibit resistance to current checkpoint inhibitors, necessitating combination strategies.
  • The 'non-inflamed' tumor phenotype, characterized by insufficient tumor-specific T cells, limits treatment efficacy.

Purpose of the Study:

  • To review preclinical and clinical data on combining cancer vaccines with anti-CTLA-4 and anti-PD-1/PD-L1 antibodies.
  • To evaluate the potential of enhancing T cell activation in combination cancer therapies.
  • To explore strategies for overcoming resistance in malignancies treated with checkpoint blockade.

Main Methods:

  • Review of preclinical studies investigating the synergistic effects of cancer vaccines and checkpoint inhibitors.
  • Analysis of clinical trial data assessing the efficacy and safety of combination therapies.
  • Evaluation of mechanisms driving T cell activation and anti-tumor responses in combined treatment settings.

Main Results:

  • Preliminary preclinical data suggest enhanced anti-tumor activity when combining cancer vaccines with checkpoint blockade.
  • Clinical study results regarding the efficacy of these combinations are currently less clear and require further validation.
  • The combination of multiple immune modulators is an active area of ongoing research.

Conclusions:

  • Combining cancer vaccines with checkpoint blockade (anti-CTLA-4, anti-PD-1/PD-L1) shows potential for improving anti-tumor responses.
  • Further clinical investigation is needed to clarify the efficacy and optimize the use of these combination strategies.
  • Future research will likely focus on broader combinations of immunomodulatory agents for enhanced cancer treatment.
Keywords:
Anti-CTLA-4Anti-PD-1Anti-PD-L1

More Related Videos

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.8K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.2K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K